4Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med, 2004,351 : 1860-1873.
5Pineda-Roman M, Barlogie B, Anaissie E, et al. High-dose melphalan-based autotransplants for multiple myeloma : the Arkansas experience since 1989 in 3077 patients. Cancer, 2008, 112: 1754-1764.
6Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin, 2007, 57:43-66.
7Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patient with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol, 1998,102:1115-1123.
8Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia,2006,20:1467- 1473.
9Durie BG. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer,2006,42 : 1539-1543.
10Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin 0ncol,2005,23:3412-3420.
